For research use only. Not for therapeutic Use.
Pirtobrutinib（Cat No.:I034845）is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor designed for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Unlike covalent BTK inhibitors, Pirtobrutinib maintains efficacy against BTK mutations that can lead to drug resistance. By reversibly inhibiting BTK, it disrupts B-cell receptor signaling, which is crucial for the survival and proliferation of malignant B cells. Pirtobrutinib offers a promising option for patients with relapsed or refractory B-cell cancers, particularly those resistant to other BTK inhibitors.
| Catalog Number | I034845 |
| CAS Number | 2101700-15-4 |
| Synonyms | 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide |
| Molecular Formula | C22H21F4N5O3 |
| Purity | 97% |
| Target | BTK |
| Target Protein | Q8JH64 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | BTK Ki IC50: 3.15 nM |
| IUPAC Name | 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide |
| InChI | InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1 |
| InChIKey | FWZAWAUZXYCBKZ-NSHDSACASA-N |
| SMILES | C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N |
| Reference | [1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644. |
